Results 131 to 140 of about 3,377,134 (229)

Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)

Obesity Reviews, EarlyView.
Challenges and evidence in obesity guidelines. ABSTRACT Obesity remains a global health crisis characterized by substantial heterogeneity in diagnosis, management, and policy implementation. Although numerous national and international clinical practice guidelines have been published over the past decade, their translation into evidence‐based and ...
Rosero‐Revelo Ricardo, Tamayo Mateo, Henao Diana, Juan P. Polanco, Cortés David, Juan C. Alba, Giha Valeria, Camargo Camilo, Hernández Eder, Correa Ricardo, Nassar Ricardo, Cabandugama Peminda, Marcio L. Griebeler, Burguera Bartolome   +13 more
wiley   +1 more source

Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan

Obesity Reviews, EarlyView.
ABSTRACT Obesity arises from intertwined and reciprocal diet‐microbiome‐host pathways that reshape energy balance, insulin sensitivity, and inflammation. This review synthesizes mechanistic links between microbial functions and metabolic control, charts lifestyle‐related lifecourse dynamics from birth to older age, examines how GLP‐1‐based therapies ...
Ioanna Panagiota Kalafati, David Krongauz, Alice Bosco, Antonio Noto, Cristina Piras, Maria Kafyra, Angelica Dessì, Matteo Mauri, Luigi Atzori, Adina Weinberger, Vassilios Fanos, George V. Dedoussis, on behalf of the BETTER4U consortium   +12 more
wiley   +1 more source

Beyond weight loss: Preserving muscle health in the incretin era

Journal of Diabetes Investigation, EarlyView.
Toshinori Imaizumi, Daisuke Yabe
wiley   +1 more source

Lifestyle modification in atrial fibrillation: Mechanisms, phenotypes and ablation outcomes

Experimental Physiology, EarlyView.
Abstract Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia and is associated with significant morbidity, mortality and healthcare utilization. Catheter ablation is increasingly used as a rhythm‐control intervention for patients with symptomatic paroxysmal and persistent AF, yet recurrence rates remain suboptimal.
Konstantinos Grigoriou, Paschalis Karakasis, Panagiotis Theofilis, Konstantinos Pamporis, Panayotis K. Vlachakis, Anastasios Apostolos, Nikolaos Ktenopoulos, Barbara Fyntanidou, Efstratios Karagiannidis, Dimitrios Patoulias, Antonios P Antoniadis, Nikolaos Fragakis   +11 more
wiley   +1 more source

One Size Fits None: Developing a Person‐Centered Approach to Weight Management in Older Adults

Journal of the American Geriatrics Society, EarlyView.
Aruna V. Josyula, Jennifer Muniak, Anushka Tandon, Noelle Marie Javier, Michi Yukawa, Colleen Christmas, Timothy W. Farrell   +6 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies

Clinical Obesity, Volume 16, Issue 5, October 2026.
ABSTRACT This systematic review and meta‐analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow‐up.
Giovanna Pagani Paccola, Roberta Fernandes de Oliveira, Matheus Menão Mochetti, Fernanda Pataro Marsola Razera, Rafael Vecchi, Renan Canale Peres Montanher   +5 more
wiley   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8757-8768, October 2026.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9621-9632, October 2026.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8769-8776, October 2026.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source